摘要
目的探讨白血病、淋巴瘤、多发性骨髓瘤等恶性血液病患者体内可溶性人类白细胞抗原Ⅰ(sHLA-Ⅰ)水平的变化及其临床意义。方法用ELISA方法检测112例恶性血液病患者的血清sHLAⅠ-水平。结果血清sHLAⅠ-水平白血病、多发性骨髓瘤、淋巴瘤均高于正常对照组(P均<0.01),淋巴瘤、多发性骨髓瘤高于白血病(P均<0.05),淋巴瘤组与多发性骨髓瘤组比较无统计学意义(P>0.05);白血病初治组、复发或未缓解组血清sHLAⅠ-水平高于缓解组(P均<0.01),初治组与复发组比较无统计学意义(P>0.05)。血清sHLAⅠ-水平与患者外周血乳酸脱氢酶及β2-微球蛋白水平有关。结论血清sHLAⅠ-可以作为一种辅助监测及判断恶性血液病预后及复发的指标。
Objective To investigate the clinical significance of the level of serum soluble human leukocyte antigens Ⅰ （sHLA-Ⅰ） in patients with acute leukemia, lymphoma or multiple myeloma. Methods Concentrations of serum sHLA-Ⅰ in 112 patients with acute leukemia, lymphoma multiple myeloma were determined by enzyme linked immunosorbent assay. Results Concentrations of serum sHLA-Ⅰ in acute leukemia, lymphoma multiple myeloma patients were significantly increased compared with normal control（ all P 〈 0.01 ）. The levels of sHLA-Ⅰ of Lymphoma and multiple myeloma patients were significantly higher than those of acute leukemia subjects （all P 〈 0.05 ）, but no difference was detected between lym- phoma and multiple myeloma（P 〉0.05）. The sHLA-Ⅰ levels in untreated and relapsed patients were significantly higher than those in the complete remission subjects（ all P 〈0.01 ） , while there was no difference between the untreated and relapsed patients significantly（P 〉 0.05）. The serum level of sHLA-Ⅰ was closely correlated with the peripheral leukocytes and contents of serum LDH as well as β2 macroglobulin. Conclusions Serum sHLA-Ⅰ can be as a prognosis and relapse index for malignant hemopathy.
出处
《山东医药》
CAS
北大核心
2010年第13期16-18,共3页
Shandong Medical Journal
